TRAITEMENT DE MALADIES ASSOCIÉES AU RÉCEPTEUR DE FACTEUR NÉCROSANT DES TUMEURS 2 (TNFR2) PAR INHIBITION DE LA TRANSCRIPTION ANTISENS NATURELLE DE TNFR2
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Necrosis Factor Receptor 2 (TNFR2), in particular, by targeting natural antisense polynucleotides of Tumor Necrosis Factor Receptor 2 (TNFR2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TNFR2.